Conditions: Gout
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 1735
Healthy volunteers: no

Brief summary:
This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.

Detailed description:

Arms:
arm 1: Treatment.

Interventions: intervention 1: Allopurinol
Intervention descriptions: intervention 1: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.

Protocol document: